Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/MIN-202> ?p ?o }
Showing triples 1 to 42 of
42
with 100 triples per page.
- MIN-202 abstract "MIN-202 is a selective, small-molecule antagonist of the OX2 receptor which is under development by Minerva Neurosciences in association with Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia. As of 2014, it is in phase I clinical trials for this indication. The chemical structure of MIN-202 has yet to be disclosed.".
- MIN-202 wikiPageExternalLink minervaneurosciences.com.
- MIN-202 wikiPageID "44927187".
- MIN-202 wikiPageLength "1342".
- MIN-202 wikiPageOutDegree "17".
- MIN-202 wikiPageRevisionID "663737638".
- MIN-202 wikiPageWikiLink Category:Hypnotics.
- MIN-202 wikiPageWikiLink Category:Orexin_antagonists.
- MIN-202 wikiPageWikiLink Chemical_structure.
- MIN-202 wikiPageWikiLink Clinical_trial.
- MIN-202 wikiPageWikiLink EMPA_(drug).
- MIN-202 wikiPageWikiLink Filorexant.
- MIN-202 wikiPageWikiLink Hypocretin_(orexin)_receptor_2.
- MIN-202 wikiPageWikiLink Insomnia.
- MIN-202 wikiPageWikiLink Janssen_Pharmaceutica.
- MIN-202 wikiPageWikiLink Johnson_&_Johnson.
- MIN-202 wikiPageWikiLink Lemborexant.
- MIN-202 wikiPageWikiLink Minerva_Neurosciences.
- MIN-202 wikiPageWikiLink Phase_1.
- MIN-202 wikiPageWikiLink Phase_I.
- MIN-202 wikiPageWikiLink Receptor_antagonist.
- MIN-202 wikiPageWikiLink Small-molecule.
- MIN-202 wikiPageWikiLink Small_molecule.
- MIN-202 wikiPageWikiLink Suvorexant.
- MIN-202 wikiPageWikiLink TCS-OX2-29.
- MIN-202 wikiPageWikiLinkText "MIN-202".
- MIN-202 hasPhotoCollection MIN-202.
- MIN-202 wikiPageUsesTemplate Template:Insomnia_pharmacotherapies.
- MIN-202 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- MIN-202 wikiPageUsesTemplate Template:Neuropeptidergics.
- MIN-202 wikiPageUsesTemplate Template:Reflist.
- MIN-202 subject Category:Hypnotics.
- MIN-202 subject Category:Orexin_antagonists.
- MIN-202 hypernym Antagonist.
- MIN-202 type Drug.
- MIN-202 comment "MIN-202 is a selective, small-molecule antagonist of the OX2 receptor which is under development by Minerva Neurosciences in association with Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia. As of 2014, it is in phase I clinical trials for this indication. The chemical structure of MIN-202 has yet to be disclosed.".
- MIN-202 label "MIN-202".
- MIN-202 sameAs m.012l6cnh.
- MIN-202 sameAs Q19597962.
- MIN-202 sameAs Q19597962.
- MIN-202 wasDerivedFrom MIN-202?oldid=663737638.
- MIN-202 isPrimaryTopicOf MIN-202.